It's possible the dose-dependency presentation is a "placeholder" for the company's AAIC registration. It is just the most recent AD-related data they released and they may actually hope/intend to present Part B results but cannot and thus will not commit to it. I suspect that if Part B results are available in the interim they have the liberty of changing the presentation.
Market Data 
Markets 
AI
